| Literature DB >> 27266262 |
Vibhav Rangarajan1, Satish Jacob Chacko1, Simone Romano2, Jennifer Jue1, Nikhil Jariwala1, Jaehoon Chung1, Afshin Farzaneh-Far3,4.
Abstract
BACKGROUND: Left ventricular pump function requires a complex interplay involving myocardial fibers orientated in the longitudinal, oblique and circumferential directions. Long axis dysfunction appears to be an early marker for a number of pathological states. We hypothesized that mitral annular plane systolic excursion (MAPSE) measured during cine-cardiovascular magnetic resonance (CMR) reflects changes in long axis function and may be an early marker for adverse cardiovascular outcomes. The aims of this study were therefore: 1) To assess the feasibility and reproducibility of MAPSE measurements during routine cine-CMR; and 2) To assess whether MAPSE, as a surrogate for long axis function, is a predictor of major adverse cardiovascular events (MACE).Entities:
Keywords: Atrioventricular plane displacement (AVPD); Cardiovascular magnetic resonance; Left ventricular function; Longitudinal strain; Mitral annular plane systolic excursion; Prognosis
Mesh:
Year: 2016 PMID: 27266262 PMCID: PMC4897936 DOI: 10.1186/s12968-016-0257-y
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Fig. 1Measurement of MAPSE. Septal and lateral mitral annular positions were recorded at end diastole (left panel, purple line) and end systole (right panel, blue line), allowing for assessment of lateral (right panel, red line) and septal MAPSE (right panel, orange line)
Baseline Characteristics Stratified by Median Level of MAPSE
| Characteristics | Total | Lateral MAPSE < median | Lateral MAPSE ≥ median |
|
|---|---|---|---|---|
|
|
|
| ||
| Age (±SD) | 57.9 (±14.7) | 59.7 (±14.6) | 56.2 (±14.6) | 0.017 |
| Male % | 44.8 | 47.7 | 42.0 | 0.248 |
| BMI (±SD) | 30.6 (±6.4) | 31.0 (±6.5) | 31.1 (±6.3) | 0.876 |
| Diabetes % | 32.5 | 38.5 | 26.8 | 0.013 |
| Hyperlipidemia % | 52.0 | 56.9 | 47.3 | 0.055 |
| Smoking % | 18.0 | 23.6 | 12.7 | 0.005 |
| Hypertension % | 73.8 | 76.4 | 71.2 | 0.238 |
| Known CAD % | 31.1 | 36.6 | 25.9 | 0.020 |
| Prior MI % | 13.3 | 16.4 | 10.2 | 0.069 |
| Prior PCI % | 15.8 | 19.5 | 12.2 | 0.045 |
| Prior CABG % | 3.8 | 3.1 | 4.4 | 0.490 |
| NYHA class | 0.6 (±0.9) | 0.5 (±0.9) | 0.6 (±1.0) | 0.295 |
| Heart Failure % | ||||
| None | 69.2 | 70.7 | 67.8 | 0.543 |
| NYHA 1 | 12.1 | 12.6 | 11.6 | 0.760 |
| NYHA 2 | 12.3 | 11.5 | 13.1 | 0.642 |
| NYHA 3 | 5.4 | 4.7 | 6.0 | 0.564 |
| NYHA 4 | 0.5 | 0.5 | 0.5 | 0.977 |
| Antiplatelet Drug % | 53.3 | 52.5 | 54.1 | 0.788 |
| Statin % | 50.1 | 49.6 | 52.1 | 0.684 |
| ACE inhibitor % | 40.4 | 43.9 | 40.0 | 0.235 |
| Beta Blocker % | 64.2 | 64.7 | 63.7 | 0.853 |
| Diuretic % | 46.5 | 42.0 | 50.7 | 0.144 |
| LVEF (±SD) | 58.9 (±13.7) | 55.5 (±15.6) | 62.2 (±10.7) | <0.001 |
| LV mass g (±SD) | 118.8 (±43.3) | 123.6 (±48.1) | 114.6 (±38.3) | 0.039 |
| LGE present % | 20.9 | 26.7 | 15.3 | 0.006 |
ACE angiotensin converting enzyme, BMI body mass index, CABG coronary artery bypass grafting, CAD coronary artery disease, LGE late gadolinium enhancement, LVEF left ventricular ejection fraction, MAPSE Mitral Annular Plane Systolic Excursion, MI myocardial infarction, NYHA class New York Heart Association Class (class 0 signifies no heart failure), PCI percutaneous coronary intervention, SD standard deviation
Fig. 2Bland-Altman analysis of lateral MAPSE for a interobserver and b intraobserver variability. Solid line represents the bias. Dashed line represents the limits of agreement
Fig. 3Kaplan-Meier curves for MACE, in patients with lateral MAPSE above and below the median. The number of patients at risk at each time interval for each group is presented
Fig. 4Overall incidence of MACE stratified by lateral MAPSE and LVEF
Univariable and multivariable predictors of MACE
| Variables | Univariable | Multivariable | ||
|---|---|---|---|---|
| Hazard Ratio |
| Hazard Ratio |
| |
| Age | 1.016 (0.999–1.033) | 0.0585 | 0.985 (0.958–1.013) | 0.286 |
| Male | 1.014 (0.638–1.612) | 0.9531 | - | - |
| Diabetes | 1.693 (1.058–2.713) | 0.0309 | 0.863 (0.428–1.740) | 0.680 |
| Hyperlipidemia | 1.326 (0.825–2.131) | 0.2397 | - | - |
| Smoking | 0.998 (0.555–1.795) | 0.9953 | - | - |
| Hypertension | 2.482 (1.189–5.181) | 0.0066 | 2.355 (0.820–6.766) | 0.112 |
| NYHA class | 0.810 (0.618–1.060) | 0.1080 | 0.853 (0.519–1.403) | 0.532 |
| LVEF | 1.001 (0.985–1.017) | 0.9234 | - | - |
| LGE present | 1.263 (0.757–2.110) | 0.3794 | - | - |
| LV mass | 1.009 (1.002–1.017) | 0.0211 | 1.008 (1.000–1.015) | 0.044 |
| Lateral MAPSEa | 2.228 (1.051–4.679) | 0.0331 | 4.384 (1.257–15.271) | 0.020 |
| Septal MAPSEa | 1.585 (0.682–3.715) | 0.2865 | - | - |
LGE late gadolinium enhancement, LV left ventricular, LVEF left ventricular ejection fraction, MAPSE Mitral Annular Plane Systolic Excursion, NYHA New York Hear Association. aper cm decrease
Fig. 5Risk reclassification. Illustration of risk reclassification by addition of lateral MAPSE to a model containing ejection fraction, age, diabetes, hypertension, NYHA class and LV mass. The upper horizontal bar graph represents the distribution of risk across categories of MACE as estimated by the model prior to adding lateral MAPSE. The pie graphs represent the proportions of patients in each pre-lateral MAPSE category reassigned to each risk category after the addition of lateral MAPSE to the risk model. The vertical bar charts at the bottom represent the annualized rates of MACE in each of the post-lateral MAPSE risk categories